HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons.

Autor:	Poloznikov AA; Faculty of Biology and Biotechnology, HSE University, Moscow, Russia., Nersisyan SA; Faculty of Biology and Biotechnology, HSE University, Moscow, Russia., Hushpulian DM; P. A. Hertsen Moscow Oncology Research Center, Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, Russia.; School of Biomedicine, Far Eastern Federal University, Vladivostok, Russia., Kazakov EH; Department of Anatomy and Cell Biology, New York Medical College, Valhalla, NY, United States., Tonevitsky AG; Faculty of Biology and Biotechnology, HSE University, Moscow, Russia., Kazakov SV; Department of Chemistry and Physical Sciences, Dyson College of Arts and Sciences, Pace University, Pleasantville, NY, United States., Vechorko VI; City Clinical Hospital No 15 Named After O. M. Filatov, Moscow, Russia., Nikulin SV; Faculty of Biology and Biotechnology, HSE University, Moscow, Russia., Makarova JA; Faculty of Biology and Biotechnology, HSE University, Moscow, Russia., Gazaryan IG; P. A. Hertsen Moscow Oncology Research Center, Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, Russia.; Department of Anatomy and Cell Biology, New York Medical College, Valhalla, NY, United States.; Department of Chemistry and Physical Sciences, Dyson College of Arts and Sciences, Pace University, Pleasantville, NY, United States.; Chemical Enzymology Department, M. V. Lomonosov Moscow State University, Moscow, Russia.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2021 Jan 29; Vol. 11, pp. 621054. Date of Electronic Publication: 2021 Jan 29 (Print Publication: 2020).
DOI:	10.3389/fphar.2020.621054
Abstrakt:	The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia inducible factor (HIF). Recombinant Epo treatment has anti-inflammatory and healing properties, and thus, very likely, will be beneficial for moderate to severe cases of COVID-19. However, HIF PHD inhibition may have a significantly broader effect, in addition to stimulating the endogenous Epo production. The analysis of HIF target genes reveals that some HIF-targets, such as furin, could play a negative role with respect to viral entry. On the other hand, HIF prolyl hydroxylase inhibitors counteract ferroptosis, the process recently implicated in vessel damage during the later stages of COVID-19. Therefore, HIF prolyl hydroxylase inhibitors may serve as a promising treatment of COVID-19 complications, but they are unlikely to aid in the prevention of the initial stages of infection. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Poloznikov, Nersisyan, Hushpulian, Kazakov, Tonevitsky, Kazakov, Vechorko, Nikulin, Makarova and Gazaryan.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu